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ABSTRACT 
Primary biliary cirrhosis in combination with autoimmune hepatitis has been termed “overlap syndrome”, but its 
diagnosis is challenging. We report a case of a 43-year-old lady who presented with a six-month history of 
jaundice and pruritus. She subsequently developed gum bleeds. Laboratory investigations revealed hypochromic 
microcytic anemia, abnormal coagulation profiles, elevated serum alanine transferase and alkaline phosphatase 
levels, and raised serum IgG and IgM levels. Her serum was also positive for anti-nuclear and anti-mitochondrial 
antibodies. The findings from her abdominal CT scan were suggestive of early liver cirrhosis and the 
histopathological examination results of her liver biopsy were consistent with primary biliary cirrhosis. The 
patient was treated with ursodeoxycholic acid and her liver function test parameters normalized after six months. 
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INTRODUCTION 
Autoimmune hepatitis (AIH), primary 
biliary cirrhosis (PBC) and primary 
sclerosing cholangitis (PSC) are autoimmune 
liver diseases. These conditions can be 
differentiated based on clinical, biochemical, 
immunological and histological features. 
They are classically viewed as distinct 
entities although shared patterns across the 
spectrum have been recognized (Silveira, 
2013). Primary biliary cirrhosis (PBC) is a 
chronically progressive cholestatic disease of 
the liver. It is characterized by immune-
mediated destruction of small intra-hepatic 
bile ducts, causing cholestasis initially and 
later cirrhosis. The autoimmune basis of 
PBC is supported by the presence of specific 
anti-mitochondrial antibodies (AMA) and 
auto-reactive T cells (Bowlus and Gershwin, 
2014). Autoimmune hepatitis (AIH) is a 
progressive inflammatory liver disorder 
characterized by inflammatory liver 
histology, circulating non-organ-specific 
autoantibodies, and increased levels of 
immunoglobulin G but with an unknown 
etiology (Mieli-Vergani et al., 2009).  
 
CASE REPORT 
A 43-year-old Malay housewife with no 
previous medical history noticed yellowish 
discoloration of her sclera and skin 
associated with generalized pruritis for six 
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months. She initially visited the general 
practitioner, who screened her for viral hepa-
hepatitis but she was negative for hepatitis B 
and C. Subsequently, she developed gum 
bleeds and was investigated in UKM 
Medical Centre where she also received a 
blood transfusion due to low hemoglobin (4 
g/dL). She was asymptomatic for anemia and 
had no symptoms of biliary obstruction. She 
does not consume alcohol or traditional 
remedies. On examination, she was 
jaundiced and pale. She had clubbed fingers, 
but there were no stigmata of chronic liver 
disease. Abdominal examination revealed 
hepatomegaly. Her relevant blood 
investigation results are shown in Table 1. 
A full blood picture (FBP) examination 
showed microcytic hypochromic 
erythrocytes with anisopoikilocytosis, which 
was compatible with iron deficiency 
anaemia. Her alpha-fetoprotein level was 
normal. An abdominal CT scan showed ill-
defined hypodensities in the liver, suggesting 
regenerating nodules of early liver cirrhosis. 
Further immunological investigations 
showed raised serum immunoglobulins M 
and G levels (355 and 2870 mg/dL 
respectively), but the immunoglobulin A 
level was normal. Serum anti-nuclear 
antibodies (ANA) were detected and formed 
a speckled pattern on HEp-2 cells. Anti-
mitochondrial antibodies were also positive 
up to a titre of 1:80. Anti-double stranded 
DNA and anti-smooth muscle antibodies 
were not detected. The provisional diagnosis 
of primary biliary cirrhosis with possible 
autoimmune hepatitis was made.  
Four months later, she presented again 
with severe anemia (hemoglobin of 2.5 g/dL) 
secondary to menorrhagia and coagulopathy. 
She was transfused with six units of packed 
cells and four units of fresh frozen plasma. 
Further investigations of her anemia were 
undertaken. A bone marrow examination 
revealed erythroid hyperplasia, in keeping 
with iron deficiency. Thalassemia was ruled 
out by haemoglobin analysis. A liver biopsy 
showed mild to moderate chronic 
inflammatory portal tract infiltrates 
consisting of lymphocytes, polymorphs and 
plasma cells. These cells expanded and 
partially obliterated the tracts. There was 
also significant portal fibroplasia, bile 
ductular proliferation, portal-to-portal 
reticulin collapse and fibrosis. Intra-
cytoplasmic and canalicular cholestasis were 
noted. Lobular inflammation was present but 
with no hepatocellular necrosis.
 
Table 1: Relevant blood investigation parameters and their results 
Parameter Result Reference range Flag 
Haemoglobin 4 g/dL 12-16 g/dL Low 
Total white cell count 5.6 x 109 /L 4-10 x 109 /L Normal 
Platelet count 150 x 109 /L 150-400 x 109/L Normal 
Mean corpuscular volume 71.6 fl 77-91 fl Low 
Mean corpuscular haemoglobin 22.3 pg 26-32 pg Low 
Prothrombin time 45.1 secs 11.6-14.1 secs Prolonged 
Activated partial thromboplastin time 94 secs 30.16-44.29 secs Prolonged 
International normalized ratio (INR) 5.33 - High 
Total albumin 37 g/L 25-50 g/L Normal 
Total protein 75 g/L 67-88 g/L Normal 
Total bilirubin 98 μmol/L <23 μmol/L Raised 
Iron 3.3 μmol/L 5-29 μmol/L Low 
Total iron binding capacity 118 μmol/L 44-75 μmol/L High 
Alanine transferase (ALT) 88 U/L < 44 U/L Raised 
Alkaline phosphatase (ALP) 408 U/L 32-104 U/L Markedly raised 
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These features were consistent with 
active primary biliary cirrhosis and the 
patient was treated with ursodeoxycholic 
acid (UDCA) (750 mg od; 15 mg/kg/day). 
Ferrous fumarate (200 mg tds) was also 
given for the anemia. Her liver function test 
parameters improved a month post discharge 
from our hospital and they normalized 
during a follow-up at six months. 
 
DISCUSSION 
Despite the absence of standard 
diagnostic criteria and the lack of agreement 
on what constitutes an overlap syndrome, 
PBC with AIH overlaps are recognised, 
consisting of conditions exhibiting features 
of both entities. The prevalence varies 
widely from 1 to 19 percent in patients 
initially diagnosed with PBC (Silveira, 2013; 
Heneghan, 2014). Interestingly, the features 
of autoimmune hepatitis may be present at 
diagnosis or during follow-up, with clinical 
recognition being somewhat easier in the 
latter. Alternately, PBC may also develop in 
patients who present with AIH (Heneghan, 
2014). Although overlap syndrome has been 
considered a clinical entity characterized by 
the occurrence of both conditions simul-
taneously, the transition of one condition to 
the other has also been reported, and AIH 
superimposed upon PBC may lead to a rapid 
progression to cirrhosis and liver failure 
(Poupon et al., 2006).  
The PBC diagnostic criteria include 
serum ALP levels raised at least two times 
the upper limit of normal or serum gamma-
glutamyl transpeptidase levels raised at least 
five times the upper limit of normal, a 
positive test for AMA, and a liver biopsy 
showing florid duct lesions (Silveira, 2013). 
The AIH diagnostic criteria include raised 
serum ALT levels at least five times the 
upper limit of normal, raised serum IgG 
levels at least two times the upper limit of 
normal or the presence of anti-smooth 
muscle antibody, and a liver biopsy showing 
moderate to severe periportal or periseptal 
lymphocytic piecemeal necrosis (Silveira, 
2013). Our patient fulfilled one AIH 
criterion and all of the PBC criteria. The 
diagnosis of PBC-AIH overlap syndrome is 
confirmed when at least two out of three of 
both criteria are met either simultaneously or 
consecutively (Silveira, 2013).  
The presence of ANAs in a patient with 
autoimmune liver disease can be divided into 
several categories but ANA patterns such as 
“rim-like” and “multinuclear dots” are likely 
to be associated with PBC (Romero-Gómez 
et al., 2004). In AIH, the ANA pattern seen 
is usually homogeneous (Mieli-Vergani and 
Vergani, 2011). In this patient, her ANA had 
a speckled pattern, which is most likely 
PBC-related. Liver histology plays an 
important role in diagnosis. Pathological 
changes in the portal tracts signify PBC, and 
lobular inflammation has been taken as a 
feature suggesting AIH in one study (Joshi et 
al., 2002).  
The International Autoimmune Hepatitis 
Group (IAIHG) in 2011 issued a consensus 
statement noting that patients with primary 
biliary cirrhosis with features of autoimmune 
hepatitis are to be considered for immuno-
suppressive treatment (Boberg et al., 2011). 
The therapeutic goal is to attain normal 
serum aminotransferase levels and histolo-
gical improvement. Combination treatment 
of glucocorticoids and UDCA is effective in 
improving liver histology within seven years 
of follow-up in patients conforming to a 
strictly defined PBC-AIH overlap syndrome, 
as opposed to UDCA or corticosteroids alone 
(Chazouillères et al., 1998). In our patient, 
an improvement in her liver function test 
was documented during follow-up, despite 
not being treated with corticosteroids. 
In conclusion, the diagnosis of overlap 
syndrome is challenging but it is imperative 
to diagnose due to its rapid progression to 
cirrhosis and liver failure. Patients with 
laboratory results diagnostic of PBC coupled 
with findings suggestive of AIH should be 
carefully followed-up. They may be treated 
with ursodeoxycholic acid initially but be 
considered for a trial of corticosteroids if no 
improvement in the liver function is 
observed during follow-up.  
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